These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17652621)

  • 41. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
    Haan S; Wüller S; Kaczor J; Rolvering C; Nöcker T; Behrmann I; Haan C
    Oncogene; 2009 Aug; 28(34):3069-80. PubMed ID: 19543316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.
    Van Roosbroeck K; Cox L; Tousseyn T; Lahortiga I; Gielen O; Cauwelier B; De Paepe P; Verhoef G; Marynen P; Vandenberghe P; De Wolf-Peeters C; Cools J; Wlodarska I
    Blood; 2011 Apr; 117(15):4056-64. PubMed ID: 21325169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma.
    Ritz O; Guiter C; Dorsch K; Dusanter-Fourt I; Wegener S; Jouault H; Gaulard P; Castellano F; Möller P; Leroy K
    Leukemia; 2008 Nov; 22(11):2106-10. PubMed ID: 18401415
    [No Abstract]   [Full Text] [Related]  

  • 45. Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia.
    Zhang XH; Yang L; Liu XJ; Zhan Y; Pan YX; Wang XZ; Luo JM
    Oncol Rep; 2018 Aug; 40(2):1008-1016. PubMed ID: 29916533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential thrombocythemia.
    Födermayr M; Zach O; Huber M; Machherndl-Spandl S; Wölfl S; Bösmüller HC; Hasenschwandtner S; Burgstaller S; Krieger O; Lutz D; Weltermann A; Hauser H
    Leuk Res; 2012 May; 36(5):588-90. PubMed ID: 22325365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
    Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
    Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms.
    Fernández-Mercado M; Cebrián V; Euba B; García-Granero M; Calasanz MJ; Novo FJ; Vizmanos JL; García-Delgado M
    Leuk Res; 2008 Oct; 32(10):1638-40. PubMed ID: 18440067
    [No Abstract]   [Full Text] [Related]  

  • 52. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation].
    Weniger MA; Melzner I; Menz CK; Wegener S; Bucur AJ; Dorsch K; Mattfeldt T; Barth TF; Möller P
    Verh Dtsch Ges Pathol; 2006; 90():210-5. PubMed ID: 17867599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Research advances in the role of JAK2 mutations in acute leukemia].
    Zhang HY; Zhai XW
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.
    Reddy PN; Sargin B; Choudhary C; Stein S; Grez M; Müller-Tidow C; Berdel WE; Serve H; Brandts CH;
    Blood; 2012 Aug; 120(8):1691-702. PubMed ID: 22517899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries.
    Doti N; Scognamiglio PL; Madonna S; Scarponi C; Ruvo M; Perretta G; Albanesi C; Marasco D
    Biochem J; 2012 Apr; 443(1):231-40. PubMed ID: 22166051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].
    Zhao YL; Liu GM; Zhang LJ; Liang WT; Cheng ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1275-9. PubMed ID: 27531815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.
    Dusa A; Staerk J; Elliott J; Pecquet C; Poirel HA; Johnston JA; Constantinescu SN
    J Biol Chem; 2008 May; 283(19):12941-8. PubMed ID: 18326042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
    Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
    Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activating STAT6 mutations in follicular lymphoma.
    Yildiz M; Li H; Bernard D; Amin NA; Ouillette P; Jones S; Saiya-Cork K; Parkin B; Jacobi K; Shedden K; Wang S; Chang AE; Kaminski MS; Malek SN
    Blood; 2015 Jan; 125(4):668-79. PubMed ID: 25428220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.